Arca
Skip to content
Tools
Tools

Sleep apnea

Drug research and approvals for sleep apnea: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 330 studies of sleep apnea are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 330
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 330 recruiting on ClinicalTrials.gov ↗

How its trials ended

2,273 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 496 whose ending is known, 42% met their primary endpoint, 7% missed it and 51% stopped early.

  • Completed, result not reported98944%
  • Ongoing41818%
  • Status unknown37016%
  • Met its primary endpoint2089%
  • Stopped: other or unclear1487%
  • Stopped: enrollment or feasibility713%
  • Missed its primary endpoint372%
  • Stopped: lack of efficacy10<1%
  • Stopped: funding9<1%
  • Stopped: sponsor or business decision8<1%
  • Stopped: safety5<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 6, 2026A master protocol for phase 3 randomized, double-blind, placebo-controlled studies to investigate the efficacy and safety of once weekly eloralintide in adult…Eloralintide (LY3841136)Eli LillyOngoing
Oct 24, 2025A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of maridebart cafraglutide in adult…Maridebart cafraglutide (amg 133)AmgenOngoing
Jun 14, 2024A phase 3 open label continuation protocol of a fixed dose combination of aroxybutynin and atomoxetine (AD109) in obstructive sleep apneaAD109 (atomoxetine-aroxybutynin)ApnimedOngoing
Nov 8, 2023Phase 3 randomized double-blind placebo-controlled 6-month parallel-arm study to compare a fixed dose combination of aroxybutynin/atomoxetine (AD109) to…Atomoxetine-aroxybutynin (AD109)ApnimedClosed
May 12, 2022Dexamethasone as a novel treatment for obstructive sleep apnea in childrenDexamethasoneThe Hospital for Sick ChildrenOngoing
Jun 18, 2021Solriamfetol's effect on cognitive health in apnea participants during a randomized placebo-controlled study (SHARP): a 5-week double-blind,…Solriamfetol (JZP-110)Jazz PharmaceuticalsOngoing
Jul 3, 2019Combined treatment of angiotensin receptor blocker and antioxidant supplementaion as a novel adjunctive therapy for 24-hour blood pressure improvement in…Telmisartan / Alpha-lipoic acidUniversity of British Columbia, School of Health and Exercise SciencePending
Jun 5, 2015A long-term, open-label, safety and maintenance of efficacy study of JZP-110 [(r)-2-AMINO-3-phenylpropylcarbamate hydrochloride] in the treatment of excessive…JZP-110Jazz PharmaceuticalsOngoing
May 20, 2015A twelve-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP-110…JZP-110Jazz PharmaceuticalsClosed
Jun 3, 2013Cycloserine in the treatment of sleep apnea.CycloserineUniversity of ManitobaPending

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 1, 2021OzawadePitolisantBioprojet PharmaEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.